Qlucore Targets Academic and Commercial Biotech, Life Science Markets with Novo Newton Scientific Ltd
News Jan 24, 2013
Qlucore has announced an agency agreement with Novo Newton Scientific Ltd. Novo Newton will assist in marketing Qlucore's Omics Explorer software in Ireland, Spain, Italy and South Africa. Recently Qlucore has also signed a distribution agreement in Japan, and raised investment finance for expansion into the US market.
Qlucore's intuitive software, Qlucore Omics Explorer, provides researchers with a world leading data analysis tool that is both extremely powerful and simple to use. Qlucore’s software is unique in that it allows researchers – the people with the most biological insight – to study their own data and to look for patterns and structures. Qlucore Omics Explorer is built on the premise that visualization is one of the key drivers for effective analysis of complex data in "big data" environments. As a result, researchers do not need to be statistics or computer experts in order to use Qlucore Omics Explorer effectively.
Carl-Johan Ivarsson, President, Qlucore says, "We are delighted that Novo Newton Scientific Ltd will be distributing our software into these territories. This will increase our market presence. We have been very impressed with the firm's professionalism and we are looking forward to working with the team."
Qlucore Omics Explorer is used in 19 countries by large pharmaceutical and biotech companies and renowned academic institutions. A list of scientific articles published referencing Qlucore can be found at http://www.qlucore.com/references.aspx
Tom Nugent , Chief Financial Officer , Novo Newton Scientific Ltd comments. “We are excited to collaborate with Qlucore and to be promoting Qlucore Omics Explorer. Qlucore is well respected in the scientific community and providing robust and reliable software that is well supported. The amount of genomic data is growing very quickly, and there is strong demand for high quality solutions such as Qlucore.”
Unlike most cells in the rest of our body, the DNA (the genome) in each of our brain cells varies from cell to cell, caused by somatic changes. But much remains unknown, including when these changes arise, their size and locations, and whether they are random or regulated. Now, researchers have developed new techniques allowing the detection of CNVs smaller than one million base pairs.